Wedbush Reiterates Outperform on Bicara Therapeutics, Maintains $30 Price Target

Benzinga Newsdesk www.benzinga.com Negative 52.6%

Neg 52.6% Neu 0% Pos 0%

Wedbush analyst David Nierengarten reiterates Bicara Therapeutics (NASDAQ:BCAX) with a Outperform and maintains $30 price target.